Robert E. Landry - 02 Jan 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Issuer symbol
REGN
Transactions as of
02 Jan 2024
Net transactions value
-$338,439
Form type
4
Filing time
04 Jan 2024, 16:19:09 UTC
Previous filing
29 Dec 2023
Next filing
08 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $246,337 +650 +3% $378.98 22,457 02 Jan 2024 Direct
transaction REGN Common Stock Tax liability $373,991 -421 -1.9% $888.34 22,036 02 Jan 2024 Direct
transaction REGN Common Stock Options Exercise $416,878 +1,100 +5% $378.98 23,136 03 Jan 2024 Direct
transaction REGN Common Stock Tax liability $627,662 -688 -3% $912.30 22,448 03 Jan 2024 Direct
holding REGN Common Stock 270 02 Jan 2024 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -650 -3.7% $0.000000 17,087 02 Jan 2024 Common Stock 650 $378.98 Direct F1
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1,100 -6.4% $0.000000 15,987 03 Jan 2024 Common Stock 1,100 $378.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.